Area of research
Biochemistry · Computational Theory and Mathematics
Research interest
Research interests include Eicosanoids and Hypertension Pharmacology, Computational Drug Discovery Methods, Peroxisome Proliferator-Activated Receptors, and Inflammatory mediators and NSAID effects.
Click. Screen. Degrade. A Miniaturized D2B Workflow for Rapid PROTAC Discovery
Structure-Based Design of PROTACS for the Degradation of Soluble Epoxide Hydrolase
Biochemical investigation of LC3/GABARAP-ligand interaction as an important quality measure for LC3/GABARAP-targeting small molecules: addendum to the guidelines (4th edition)
Click. Screen. Degrade. A Miniaturized D2B Workflow for rapid PROTAC Discovery
Critical assessment of LC3/GABARAP ligands used for degrader development and ligandability of LC3/GABARAP binding pockets
Development of a Potent and Selective G2A (GPR132) Agonist
Targeting LC3/GABARAP for degrader development and autophagy modulation
Multi-Target Approaches in Metabolic Syndrome
Spirocyclic Scaffolds in Medicinal Chemistry
Polypharmacology by Design: A Medicinal Chemist’s Perspective on Multitargeting Compounds
Structural Characterization of the Interaction of the Fibroblast Growth Factor Receptor with a Small Molecule Allosteric Inhibitor
Multitarget‐Directed Ligands Combining Cholinesterase and Monoamine Oxidase Inhibition with Histamine H<sub>3</sub>R Antagonism for Neurodegenerative Diseases
Opportunities and Challenges for Fatty Acid Mimetics in Drug Discovery
Nonacidic Farnesoid X Receptor Modulators
A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase To Counter Nonalcoholic Steatohepatitis
Camptothecin and its analog SN-38, the active metabolite of irinotecan, inhibit binding of the transcriptional regulator and oncoprotein FUBP1 to its DNA target sequence FUSE
Pyrazolo[1,5a]pyrimidines as a new class of FUSE binding protein 1 (FUBP1) inhibitors
Lipoxin and resolvin biosynthesis is dependent on 5‐lipoxygenase activating protein
PENG: A Neural Gas-Based Approach for Pharmacophore Elucidation. Method Design, Validation, and Virtual Screening for Novel Ligands of LTA4H
PADI4 acts as a coactivator of Tal1 by counteracting repressive histone arginine methylation
Vanillin-derived antiproliferative compounds influence Plk1 activity
The holistic integration of virtual screening in drug discovery
Inhibitors of the Arachidonic Acid Cascade: Interfering with Multiple Pathways
DOGS: Reaction-Driven de novo Design of Bioactive Compounds